H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Sana Biotechnology (SANA – Research Report) today and set a price target of $11.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Emily Bodnar’s rating is based on Sana Biotechnology’s promising clinical data and strategic advancements. The company has demonstrated encouraging results with its UP421 therapy, showcasing sustained insulin production and a favorable safety profile in Type 1 diabetes patients. This therapy, which does not require immunosuppression, has shown the ability to overcome immune recognition, evidenced by stable C-peptide levels, a marker for insulin production.
Furthermore, Sana’s ongoing Phase 1 trials for its CAR-T cell therapies, SC291 and SC262, are progressing well, with data expected soon. The company’s pipeline also includes plans to file INDs for additional therapies in 2026, indicating a robust future outlook. These developments, along with the validation of Sana’s HIP technology, underpin Bodnar’s confidence in the company’s potential, leading to the Buy rating.